Pharmaceutical Industry 13 – 19 July: Ft The Regen4HD and The Scottish Medicines Consortium
- The Regen4HD study has launched the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington’s disease.
- The Scottish Medicines Consortium has recommended Astellas’s VEOZA for eligible patients experiencing moderate to severe menopause-related hot flushes and night sweats.
Regen4HD Trial Marks Regenerative Medicine Milestone for Huntington’s Disease
The first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington’s disease has begun, marking an important milestone for regenerative medicine and the wider pharmaceutical industry.
An update on the phase 1b/2a Regen4HD study was presented at the International Society for Stem Cell Research’s ISSCR 2026 Annual Meeting.
The presentation followed years of preclinical research, translational development, pivotal safety testing and regulatory engagement focused on progressing a potential new treatment approach for Huntington’s disease.
Huntington’s disease is a progressive neurodegenerative disorder for which no disease-modifying treatments are currently available. Existing care is largely focused on managing symptoms and helping patients maintain their quality of life as the condition progresses.
Regenerative approaches using products derived from human stem cells are therefore attracting considerable interest. Researchers hope these therapies may eventually provide a way to influence the underlying disease process, rather than only addressing its symptoms.
The launch of Regen4HD represents the first time a pluripotent stem cell-derived product for Huntington’s disease has entered clinical evaluation.
Early-Stage Patients Enrolled in Safety-Focused Study
The Regen4HD study is enrolling symptomatic patients aged between 18 and 65 who are at a relatively early stage of Huntington’s disease.
Its phase 1b portion is structured as a dose-escalation study, with investigators primarily assessing the therapy’s safety and tolerability at different dose levels. This will be followed by a phase 2a stage intended to help researchers determine the maximum tolerated dose.
Because the study has only recently begun, its immediate purpose is not to prove whether the therapy can slow or reverse the progression of Huntington’s disease. Instead, researchers are concentrating on whether the treatment can be administered safely.
Exploratory measures will also be used to identify potential biological or clinical signals that could inform future studies.
These early observations may help determine how later-stage trials should be designed, including which patient populations, outcome measures and dosing strategies should be prioritised.
A professor at the University of California, Irvine, described the clinical trial as the culmination of many years of preclinical and translational research. That work included pivotal safety studies, extensive discussions with the US Food and Drug Administration and support from the California Institute for Regenerative Medicine.
The professor said reaching the point of launching the first clinical trial of a pluripotent stem cell-derived product for Huntington’s disease represented an important milestone for the field.
They also recognised the contribution of families affected by Huntington’s disease, noting that the close partnership between patients and scientists had remained a constant source of inspiration throughout the development programme.
Scientific Challenges Remain Before Therapeutic Potential Can Be Established
Developing regenerative therapies for Huntington’s disease has required researchers to overcome a number of significant scientific and clinical challenges.
These have included identifying appropriate therapeutic targets, optimising how cells are delivered and designing studies capable of measuring change in a condition that can progress gradually over many years.
Researchers must also demonstrate that manufactured cell products are consistent, stable and sufficiently characterised before they can be administered to patients. Long-term monitoring is likely to remain an important part of the clinical development process because transplanted cells may continue to survive and function after treatment.
Advances in the understanding of Huntington’s disease biology have nevertheless helped move the field closer to meaningful clinical evaluation.
The initial ambition of Regen4HD is to establish safety. Should future studies eventually demonstrate that a one-time cell therapy can slow disease progression, the approach could have considerable implications for people living with Huntington’s disease and their families.
However, investigators have stressed that these questions can only be answered through controlled and careful clinical research. The beginning of the trial should therefore be viewed as an important first step rather than evidence that the investigational therapy is already effective.
Astellas’s VEOZA Recommended for Use Through NHS Scotland
In a separate pharmaceutical development, the Scottish Medicines Consortium has recommended Astellas’s VEOZA, also known as fezolinetant, for the treatment of moderate to severe vasomotor symptoms associated with menopause.
The recommendation applies to patients for whom hormone replacement therapy is unsuitable.
It means the medicine is expected to become available through NHS Scotland, providing an additional non-hormonal option for eligible women experiencing disruptive hot flushes and night sweats.
VEOZA is administered as a 45 mg tablet taken once daily.
Approximately 400,000 women in Scotland are of menopausal age, while an estimated 48,000 could potentially benefit from access to the treatment. The medicine is the first neurokinin-targeted therapy to be accepted by the Scottish Medicines Consortium for this purpose.
The decision is particularly significant because approved non-hormonal treatment options for moderate to severe vasomotor symptoms have historically been limited.
Targeted Mechanism Offers a New Non-Hormonal Option
Fezolinetant works by selectively blocking neurokinin B, a neurotransmitter in the brain involved in the biological processes that trigger hot flushes.
Unlike hormone replacement therapy, the medicine does not replace oestrogen. It instead targets part of the neurological pathway associated with the body’s temperature regulation during menopause.
Clinical trial results submitted as part of the medicine’s UK regulatory review supported its ability to reduce the frequency and severity of vasomotor symptoms, as well as their impact on patients’ quality of life.
Across the submitted studies, the most commonly reported adverse reactions included diarrhoea, insomnia, abdominal pain and increases in the liver enzymes ALT and AST.
The recommendation will allow clinicians to consider an additional targeted treatment for appropriate patients, particularly those who cannot use hormone replacement therapy because of medical suitability, individual circumstances or other clinical considerations.
Menopause Symptoms Carry Wider Health and Economic Consequences
Hot flushes and night sweats are common during menopause, but their effects can extend far beyond temporary discomfort.
For some women, symptoms can be severe, persistent and disruptive. They may contribute to sleep disturbance, low mood, anxiety, fatigue and difficulty concentrating, with consequences for both physical and emotional wellbeing.
Greater symptom severity has also been associated with poorer overall health status, lower workplace productivity and higher levels of absenteeism and presenteeism. Patients experiencing difficult symptoms may also require more frequent contact with primary care and other healthcare services.
The medical director at Astellas UK said the company was pleased that, through close collaboration with the Scottish Medicines Consortium, the additional treatment option would become available to women in Scotland.
They said its introduction could support more personalised care for women experiencing hot flushes and night sweats.
A general practitioner also welcomed the decision, explaining that primary care professionals regularly witness the substantial effect these symptoms can have on women’s daily lives. They said the recommendation could help address long-standing inequities and provide more options for appropriate patients.
A consultant gynaecologist specialising in sexual and reproductive healthcare described the decision as a positive development for the wellbeing of Scottish women. They highlighted the impact that hot flushes and night sweats can have on sleep and overall quality of life, adding that the availability of a targeted treatment provided welcome additional choice.
Impact on Pharmaceutical Manufacturing and Production
The Regen4HD and VEOZA developments reflect two distinct but increasingly important directions for pharmaceutical manufacturing and production.
For conventional medicines such as fezolinetant, broader healthcare access creates a need for reliable tablet production, quality assurance and supply chain planning. Manufacturers must be able to respond to potential increases in NHS demand while maintaining consistent dosage, regulatory compliance and appropriate safety monitoring.
The manufacturing demands associated with pluripotent stem cell-derived therapies are considerably more complex. Cell-based products require tightly controlled production environments, specialised facilities and rigorous testing to confirm cellular identity, purity, potency and stability.
Unlike traditional tablets, living cell therapies can be sensitive to relatively small changes in culture conditions, storage, transportation and administration. Manufacturing processes must therefore be carefully standardised to ensure that every clinical dose meets the same quality specifications.
Should Regen4HD progress successfully through clinical development, its future scalability would depend not only on clinical effectiveness but also on the pharmaceutical sector’s ability to manufacture and distribute a highly specialised cell product safely and consistently.
Together, the two programmes demonstrate how pharmaceutical production is evolving to accommodate both precision small-molecule treatments and advanced regenerative medicines.
Conclusion
The beginning of the Regen4HD clinical trial and the Scottish Medicines Consortium’s recommendation of Astellas’s VEOZA illustrate the breadth of innovation currently taking place across the pharmaceutical industry.
Regen4HD represents a carefully controlled first step towards determining whether pluripotent stem cell-derived neural therapies can be safely used in people with Huntington’s disease.
While it remains too early to draw conclusions about effectiveness, the trial is the product of extensive scientific, regulatory and translational work and marks a significant milestone for regenerative medicine.
Meanwhile, the recommendation of VEOZA provides a more immediate development for women in Scotland who experience moderate to severe menopause-related hot flushes and night sweats but are unsuitable for hormone replacement therapy. Its targeted, non-hormonal mechanism expands the options available to clinicians and supports a more personalised approach to menopause care.
One development is opening a new clinical research pathway for a complex neurodegenerative condition, while the other is widening access to an already approved treatment for symptoms affecting thousands of women.
Both underline the central role of pharmaceutical research, manufacturing and healthcare collaboration in translating scientific progress into meaningful patient care.
News Credits:
Pluripotent stem cell trial for Huntington’s disease
SMC recommends VEOZA for moderate to severe menopausal vasomotor symptoms
Things you may also like:
- Pharmaceutical Industry 6 – 12 July: Ft Novartis and AlzeCure Pharma
- Pharmaceutical Industry 29 June – 5 July: Ft Agomab Therapeutics and Racura Oncology
- Pharmaceutical Industry 22 – 28 June: Ft Teva Pharmaceutical Industries and Johnson & Johnson